BeOne Secures FDA Approval for Lymphoma CAR-T, Outpacing Rivals in Cell Therapy Race
FDA Greenlights BeOne's CAR-T Therapy for Aggressive Lymphoma
Washington, D.C. – March 27, 2025 – BeOne Therapeutics received U.S. Food and Drug Administration approval today for its CAR-T cell therapy, BeOne-101, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The authorization makes BeOne the third company to win FDA clearance for a CAR-T product this year, intensifying competition in the multibillion-dollar cell therapy market.
The approval follows a priority review based on Phase 2 data showing a 72% overall response rate and a median duration of response exceeding 14 months. BeOne plans to launch the therapy at a list price of $420,000 per infusion, comparable to existing CAR-T treatments but with a streamlined manufacturing process that reduces vein-to-vein time to 12 days.
Industry and Physician Reactions
“This approval validates our proprietary rapid manufacturing platform and positions BeOne as a leader in next-generation cell therapy,” said Dr. Emily Torres, CEO of BeOne, in a press release. “We are now focused on ensuring broad patient access and expanding into earlier lines of therapy.”
Oncologists welcomed the new option. “BeOne-101 offers a potent salvage therapy for patients who have failed multiple prior regimens,” said Dr. James Liu, a lymphoma specialist at Memorial Sloan Kettering Cancer Center. “The shorter turnaround time could be particularly beneficial for those with rapidly progressing disease.”
Background: The Expanding CAR-T Landscape
CAR-T cell therapy, which engineers a patient’s own T-cells to recognize and attack cancer, has transformed lymphoma treatment since the first FDA approval in 2017. However, the technology has faced hurdles including manufacturing delays, high costs, and severe side effects like cytokine release syndrome.
BeOne’s approval comes amid a surge of investment in cell therapy. CREATE Medicines announced today it has raised $122 million in Series B funding to advance an in vivo CAR-T approach for autoimmune diseases, bypassing the need for ex vivo cell engineering. The company plans to initiate clinical trials in lupus and multiple sclerosis later this year.
Separately, the Trump administration is searching for a new FDA commissioner to replace Dr. Robert Califf, whose term ended last month. The appointment is expected to set the agency’s direction on regenerative medicine regulation, including cell therapy product oversight.
What This Means for Patients and the Market
BeOne’s entry could drive down CAR-T prices through competition while expanding the patient pool. “With three approved products, payers will gain leverage in negotiations, potentially lowering out-of-pocket costs for patients,” noted biotech analyst Sarah Chen of Leerink Partners. “The real test will be uptake and durability of response post-approval.”
For CREATE Medicines, the $122 million haul signals investor confidence in in vivo gene editing for immune diseases. If successful, the approach could eliminate the complex logistics of traditional CAR-T therapy, making cell therapy as simple as a single injection.
The FDA leadership void adds uncertainty. “A commissioner with a strong science background and a clear stance on accelerated approvals is critical for maintaining momentum in cell and gene therapy,” said Dr. Liu. “We hope the next leader prioritizes safety without stifling innovation.”
This story is developing. Check back for updates on BeOne’s launch plans and the CREATE Medicines trial initiation.